Sarepta presents 80 percent DM1 data for Sarepta Therapeutics stock

Published on 10/18/2026 at 13:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A USD 20.00 analyst target was set on October 15, 2026. Sarepta Therapeutics stock has a USD 1.8 billion market value.

Pipeline evidence and reporting date

Sarepta reported up to 80 percent SRP-1003 knockdown on October 14, 2026.
Second-quarter revenue was USD 401.25 million versus USD 611.09 million a year earlier.
Sarepta is scheduled to report third-quarter 2026 results on November 2, 2026.

SRPT, US8036071004, Illustration mit AI erstellt.

Sarepta Therapeutics (ISIN US8036071004) presented SRP-1003 data showing up to 80 percent knockdown of disease-causing DMPK RNA on October 14, 2026. According to BioSpace, the experimental treatment produced dose-dependent reductions in both nuclear and cytoplasmic DMPK messenger RNA in preclinical models. The update gives investors a measurable readout from Sarepta's early-stage myotonic dystrophy type 1 program.

SRP-1003 reaches the nucleus

The central result was biological activity in the compartment that drives the disease. Sarepta reported that SRP-1003 corrected MBNL-dependent mis-splicing and reduced toxic RNA foci across patient-derived cells and mouse models, while three independent methods supported the finding.

The preclinical signal also had a durability component. A single intravenous dose remained detectable across multiple muscle groups for up to 16 weeks in the animal studies, although the evidence remains preclinical and the ongoing Phase 1/2 trial is the next test of whether the mechanism translates to patients.

What does the recent target imply?

Leerink Partners reiterated a Hold rating and set a USD 20.00 price target in a report dated October 15, 2026, according to Markets Insider. The target sits alongside a cautious operating comparison: Sarepta reported USD 401.25 million of revenue for the quarter ended June 30, 2026, versus USD 611.09 million in the same quarter a year earlier, while the latest report showed a GAAP net loss of USD 4.89 million.

The next scheduled checkpoint is the third-quarter 2026 report on November 2, 2026, as listed by MetaCap. That release should help investors weigh the pipeline evidence against commercial performance.

Market value and next checkpoint

Sarepta had a USD 1.8 billion market capitalization as of October 16, 2026. Its business remains centered on genetic medicines for rare diseases, with SRP-1003 adding a clinical-stage RNA program to the company's Duchenne-focused portfolio.